Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Genetically Modified Stem Cells are Effective Against Acute Respiratory Diseases

Published: Tuesday, June 18, 2013
Last Updated: Tuesday, June 18, 2013
Bookmark and Share
Administration of genetically modified mesenchymal stem cells regenerates lung tissue and stops the inflammatory process in mice with acute lung injury.

Study results were published in the American Journal of Respiratory Cell and Molecular Biology.

Acute lung injury

Acute lung injury and its more severe manifestation, the acute respiratory distress syndrome, are characterized by very severe inflammatory processes that damage the lungs with a mortality of between 40% and 50%. Currently there is no effective treatment beyond palliative care and mechanical assistance to breath.

"In the last years we have been working in the administration of human mesenchymal stem cells from adipose tissue obtained from liposuction in different pathologies," said the researcher of Human Molecular Genetics reserach group at IDIBELL Josep Maria Aran. "We have found that these stem cells are able to easily reach the lungs and there, secrete anti-inflammatory substances and growth factors."

Alarm signal

The studies conducted so far with these cells have shown a positive effect. IDIBELL and VHIR researchers have introduced a genetic modification in these cells that improves treatment.

The cytokine IL33 is a protein that acts as an alarm signal in these patients. When the damage into the lungs begins, the cells secrete this highly proinflammatory substance and elicit a very strong immune system answer.

"We believed," says Aran, "that if we modified genetically mesenchymal stem cells to secrete a molecule antagonist of IL-33, we could stop the inflammatory process and we found that, in mice, the effect was more positive than unmodified cells: regeneration of lung tissue and practically nullifies the inflammatory process in the lungs. "

IDIBELL has signed a licensing agreement with the Basque company Histocell for this genetic modification and currently they are working to make this "smart drug" may reach the clinical stage and try to patients.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Patented, a Molecule that Opens the Door to Develop New Drugs Against Immune Rejection
Researchers have patented a peptide that inhibits the immune response activated by the enzyme calcineurin which could serve to develop new more specific immunosuppressive drugs.
Thursday, August 01, 2013
Identified a Key Protein in Maintaining the Identity of B Lymphocytes
This finding could be useful for the study of blood diseases such as lymphoma and leukemia.
Monday, June 10, 2013
IDIBELL Licenses to Janus a Patent for the Treatment of Immune Diseases
The technology has been developed entirely in the Institute.
Thursday, December 06, 2012
We Need Bacteria to Maintain a Good Immune System
Dr. Francisco Guarner, from the Vall d'Hebron University Hospital, talked about the functions of the bacteria in our body in the IDIBELL Seminar.
Thursday, October 25, 2012
Scientific News
Gut Bacteria Older than Human Species
Some bacteria have lived in the human gut since before we were human, suggesting evolution could have a larger role inhuman bacterial makeup.
Evidence of Mosquito Transmitting Zika
A direct link between the Yellow fever mosquito and Zika transmission has been found following investigation into selective mosquito control.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Mapping Zika’s Routes to Developing Fetus
UC researchers show how Zika virus travels from a pregnant woman to her fetus, and also identified a drug that could stop it.
Treating HIV with Cancer-Fighting Gene Shows Promise
A type of gene immunotherapy that has shown promising results against cancer could also be used against HIV.
Protein Teams Activate T-Cells
Caltech researchers have discovered T-cell genetic switching is controlled by four proteins acting in a multi-tiered fashion.
'Antigen-Presenting Cell' Defends Against Cancer
Through advanced imaging, researchers have identified cells that encourages increases in immune system cancer defences.
Zika Epidemic Likely to End Within Three Years
A team of scientists has predicted that the current Zika epidemic is likely to end within three years because there will be too few people left to infect.
Go-Between Immune Cell is Key to Priming the Body’s Fight Against Cancer
‘Antigen-presenting cell’ activates T cells by alerting them to the presence of tumors.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!